Results 31 to 40 of about 4,025 (198)

Trends and Disparities in <i>Clostridioides difficile</i> Infection Mortality in the United States From 1999 to 2020: A Nationwide Perspective. [PDF]

Gastroenterol Res Pract
Background Clostridioides difficile infection (CDI) is one of the most prevalent infections in the United States, with rising mortality and disease severity in the early 2000s, followed by a steady decline after 2010. This study analyzes national trends in CDI mortality across different demographic and regional groups from 1999 to 2020. Methods We used
Eldesouki MH, Abusalim AR, Kloub M, Umer M, Ali MA, Shaban AY, Salem A, Almoghrabi A, Slim J, Bains Y, Dacosta T.   +10 more
europepmc   +2 more sources

Antibiotic fidaxomicin is an RdRp inhibitor as a potential new therapeutic agent against Zika virus

BMC Medicine, 2020
Background Zika virus (ZIKV) infection is a global health problem, and its complications, including congenital Zika syndrome and Guillain-Barré syndrome, constitute a continued threat to humans.
Jie Yuan, Jianchen Yu, Yun Huang, Zhenjian He, Jia Luo, Yun Wu, Yingchun Zheng, Jueheng Wu, Xun Zhu, Haihe Wang, Mengfeng Li   +10 more
doaj   +1 more source

Fidaxomicin for the Treatment of Clostridioides difficile Infection in Adult Patients: An Update on Results from Randomized Controlled Trials

Antibiotics, 2022
In recently updated international guidelines, fidaxomicin is preferentially recommended as first-line treatment over vancomycin both for the first episode of CDI and for rCDI, based on the results of different randomized controlled trials (RCTs ...
Daniele Roberto Giacobbe, Antonio Vena, Marco Falcone, Francesco Menichetti, Matteo Bassetti   +4 more
doaj   +1 more source

Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infection (C. difficile-associated diarrhoea) in Ireland

Journal of Health Economics and Outcomes Research, 2015
# Background Clostridium difficile is associated with 20–30% of cases of antibiotic-associated diarrhoea. The incidence of C. difficile infection (CDI) is higher in Ireland than in other countries in Europe, and it is associated with considerable ...
Anke van Engen, Montserrat Casamayor, Fidelma Loftus, Martin Coen, Andy Garnham, Maureen Watt, Larry Lacey   +6 more
doaj   +1 more source

Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant

Hematology/Oncology and Stem Cell Therapy, 2018
Objective/background: Clostridium difficile infection (CDI) is a potential complication during hematopoietic stem cell transplantation (HSCT), and no specific recommendations exist regarding treatment of CDI in allogeneic SCT patients.
Laura Prohaska, Zahra Mahmoudjafari, Leyla Shune, Anurag Singh, Tara Lin, Sunil Abhyankar, Siddhartha Ganguly, Dennis Grauer, Joseph McGuirk, Lisa Clough   +9 more
doaj   +1 more source

Fidaxomicin [PDF]

pharma-kritik, 2015
Eine intestinale Infektion mit Clostridium difficile kann zu einer Kolitis und weiteren Darm-Komplikationen führen. Fidaxomicin ist ein neues Antibiotikum, das zur Behandlung einer solchen Erkrankung eingesetzt werden kann, wenn andere Medikamente (Metronidazol, Vancomycin) nicht genügen.
openaire   +1 more source

Biosynthetic Diversification of Fidaxomicin Aglycones by Heterologous Expression and Promoter Refactoring

, 2023
Fidaxomicin (Dificid) is a commercial macrolide antibiotic for treating Clostridium difficile infection. Total synthesis of fidaxomicin and its aglycone had been achieved through different synthetic schemes.
Yiguang Zhu (340294), Mengyi Zhu, Yiguang Zhu, Qingbo Zhang (1288581), Qingbo Zhang, Lijuan Wang, Changsheng Zhang (1450165), Shilan Zhai (15211807), Changsheng Zhang, Mengyi Zhu (4610452), Haibo Zhang, Haibo Zhang (5720), Shilan Zhai, Lijuan Wang (143209)   +13 more
core   +1 more source

Retrospective Cohort Analysis of Outpatient Antibiotic Use for Clostridioides difficile-Indicated Agents in British Columbia, from 2000 to 2018

Canadian Journal of Infectious Diseases and Medical Microbiology, 2023
Background. Clostridioides difficile (CDI) is the most common cause of nosocomial diarrheal infections. Historically, metronidazole was the first-line treatment, but guidelines now indicate oral vancomycin and fidaxomicin as primary antibiotics for ...
Ariana Saatchi, Sungeun Kim, Fawziah Marra   +2 more
doaj   +1 more source

Design, Synthesis, and Biological Evaluation of Next Generation Fidaxomicin Antibiotics [PDF]

, 2020
Natural products and natural product derived compounds are popular sources of new drugs and thus also play a pivotal role in the discovery and development of new antibiotics.
Dorst, Andrea
core   +2 more sources

Biofilm Formation of Clostridioides difficile, Toxin Production and Alternatives to Conventional Antibiotics in the Treatment of CDI

Microorganisms, 2023
Clostridioides difficile is considered a nosocomial pathogen that flares up in patients exposed to antibiotic treatment. However, four out of ten patients diagnosed with C.
Leon M. T. Dicks
doaj   +1 more source